{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:28:59Z","timestamp":1770251339236,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-02107-7","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:54:46Z","timestamp":1760363686000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial\u2014NCT 05022914)"],"prefix":"10.1007","volume":"131","author":[{"given":"Giulio","family":"Francolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Garlatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Di Cataldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Caini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Simontacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Burchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bonaparte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Frosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Serni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Vaggelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Aquilano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Raspollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mack","family":"Roach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard K.","family":"Valicenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"3","key":"2107_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000000295","volume":"202","author":"TM Pisansky","year":"2019","unstructured":"Pisansky TM, Thompson IM, Valicenti RK, D\u2019Amico AV, Selvarajah S (2019) Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018\u20132019. J Urol 202(3):533\u2013538. https:\/\/doi.org\/10.1097\/JU.0000000000000295","journal-title":"J Urol"},{"key":"2107_CR2","doi-asserted-by":"publisher","unstructured":"Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.\u00a0Urol Clin North Am. 2001;28(3):555\u2013565. https:\/\/doi.org\/10.1016\/s0094-0143(05)70163-4","DOI":"10.1016\/s0094-0143(05)70163-4"},{"issue":"1","key":"2107_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","volume":"164","author":"CL Amling","year":"2000","unstructured":"Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164(1):101\u2013105","journal-title":"J Urol"},{"issue":"2","key":"2107_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","volume":"190","author":"IM Thompson","year":"2013","unstructured":"Thompson IM, Valicenti RK, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO guideline. J Urol 190(2):441\u2013449. https:\/\/doi.org\/10.1016\/j.juro.2013.05.032","journal-title":"J Urol"},{"issue":"30","key":"2107_CR5","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar RD, Agrawal S, Gao T et al (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 34(30):3648\u20133654. https:\/\/doi.org\/10.1200\/JCO.2016.67.9647","journal-title":"J Clin Oncol"},{"issue":"1","key":"2107_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","volume":"2","author":"PJL De Visschere","year":"2019","unstructured":"De Visschere PJL, Standaert C, F\u00fctterer JJ et al (2019) A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2(1):47\u201376. https:\/\/doi.org\/10.1016\/j.euo.2018.09.010","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2107_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prnil.2018.04.005","volume":"7","author":"M Miyake","year":"2019","unstructured":"Miyake M, Tanaka N, Asakawa I et al (2019) The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. Prostate Int 7(2):47\u201353. https:\/\/doi.org\/10.1016\/j.prnil.2018.04.005","journal-title":"Prostate Int"},{"issue":"10231","key":"2107_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"2107_CR9","doi-asserted-by":"publisher","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of\u00a068Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients [published correction appears in Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1781. https:\/\/doi.org\/10.1007\/s00259-017-3763-8].\u00a0Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u20131268. https:\/\/doi.org\/10.1007\/s00259-017-3711-7","DOI":"10.1007\/s00259-017-3763-8"},{"key":"2107_CR10","doi-asserted-by":"publisher","unstructured":"Calais J, Ceci F, Eiber M, et al.\u00a018F-fluciclovine PET-CT and\u00a068Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial [published correction appears in Lancet Oncol. 2019 Nov;20(11):e613. https:\/\/doi.org\/10.1016\/S1470-2045(19)30593-5] [published correction appears in Lancet Oncol. 2020 Jun;21(6):e304. https:\/\/doi.org\/10.1016\/S1470-2045(20)30279-5].\u00a0Lancet Oncol. 2019;20(9):1286\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(19)30415-2","DOI":"10.1016\/S1470-2045(19)30593-5"},{"issue":"2","key":"2107_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046","journal-title":"Eur Urol"},{"issue":"29","key":"2107_CR12","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P et al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 40(29):3377\u20133382. https:\/\/doi.org\/10.1200\/JCO.22.00644","journal-title":"J Clin Oncol"},{"issue":"12","key":"2107_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/pros.24579","volume":"83","author":"G Francolini","year":"2023","unstructured":"Francolini G, Banini M, Di Cataldo V et al (2023) PSMA guided approach for biochemical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET\/CT within a prospective study. Prostate 83(12):1201\u20131206. https:\/\/doi.org\/10.1002\/pros.24579","journal-title":"Prostate"},{"issue":"2","key":"2107_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10585-023-10204-y","volume":"40","author":"G Francolini","year":"2023","unstructured":"Francolini G, Ganovelli M, Di Cataldo V et al (2023) Early biochemical outcomes following PSMA guided approach for bIOCHemical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results. Clin Exp Metastasis 40(2):197\u2013201. https:\/\/doi.org\/10.1007\/s10585-023-10204-y","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"2107_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11547-022-01465-w","volume":"127","author":"G Francolini","year":"2022","unstructured":"Francolini G, Jereczek-Fossa BA, Di Cataldo V et al (2022) Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. Radiol Med 127(4):449\u2013457. https:\/\/doi.org\/10.1007\/s11547-022-01465-w","journal-title":"Radiol Med"},{"issue":"3","key":"2107_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bju.14924","volume":"125","author":"G Francolini","year":"2020","unstructured":"Francolini G, Jereczek-Fossa BA, Di Cataldo V et al (2020) Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int 125(3):417\u2013425. https:\/\/doi.org\/10.1111\/bju.14924","journal-title":"BJU Int"},{"issue":"5","key":"2107_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446\u2013453. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853","journal-title":"J Clin Oncol"},{"issue":"5","key":"2107_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic Prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"key":"2107_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","volume":"176","author":"T Zilli","year":"2022","unstructured":"Zilli T, Achard V et al (2022) Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP delphi consensus. Radiother Oncol 176:199\u2013207. https:\/\/doi.org\/10.1016\/j.radonc.2022.10.005","journal-title":"Radiother Oncol"},{"issue":"1","key":"2107_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clon.2021.11.002","volume":"34","author":"G Francolini","year":"2022","unstructured":"Francolini G, Loi M, Di Cataldo V et al (2022) Stereotactic re-irradiation in recurrent prostate cancer after previous postoperative or definitive radiotherapy: long-term results after a median follow-up of 4 years. Clin Oncol (R Coll Radiol) 34(1):50\u201356. https:\/\/doi.org\/10.1016\/j.clon.2021.11.002","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"2107_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","volume":"6","author":"T Van den Broeck","year":"2020","unstructured":"Van den Broeck T, van den Bergh RCN, Briers E et al (2020) Biochemical recurrence in prostate cancer: the European association of urology prostate cancer guidelines panel recommendations. Eur Urol Focus 6(2):231\u2013234. https:\/\/doi.org\/10.1016\/j.euf.2019.06.004","journal-title":"Eur Urol Focus"},{"issue":"6","key":"2107_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki D, Preisser F, Graefen M, Huland H, Pompe RS (2019) External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol 75(6):896\u2013900. https:\/\/doi.org\/10.1016\/j.eururo.2019.03.016","journal-title":"Eur Urol"},{"key":"2107_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110215","volume":"194","author":"S Scharl","year":"2024","unstructured":"Scharl S, Zamboglou C, Strouthos I et al (2024) European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiother Oncol 194:110215. https:\/\/doi.org\/10.1016\/j.radonc.2024.110215","journal-title":"Radiother Oncol"},{"issue":"5","key":"2107_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14748","volume":"6","author":"C Zamboglou","year":"2023","unstructured":"Zamboglou C, Peeken JC, Janbain A et al (2023) Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6(5):e2314748. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14748","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2107_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092073","volume":"14","author":"T H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher T, Baumann M, Kotzerke J et al (2022) Local control after locally ablative, image-guided radiotherapy of oligometastases identified by Gallium-68-PSMA-positron emission tomography in castration-sensitive prostate cancer patients (OLI-P). Cancers (Basel) 14(9):2073. https:\/\/doi.org\/10.3390\/cancers14092073","journal-title":"Cancers (Basel)"},{"issue":"Issue 10442","key":"2107_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Amos C et al (2024) Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet 403(Issue 10442):2416\u20132425","journal-title":"Lancet"},{"issue":"5","key":"2107_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","volume":"86","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW et al (2024) Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). Eur Urol 86(5):422\u2013430. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.026","journal-title":"Eur Urol"},{"issue":"10442","key":"2107_CR28","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","volume":"1","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW et al (2024) Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet 1(10442):2405\u20132415. https:\/\/doi.org\/10.1016\/S0140-6736(24)00548-8","journal-title":"Lancet"},{"issue":"3","key":"2107_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G et al (2025) ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol 26(3):300\u2013311. https:\/\/doi.org\/10.1016\/S1470-2045(24)00730-7","journal-title":"Lancet Oncol"},{"issue":"2","key":"2107_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","volume":"85","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P et al (2024) The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies. Eur Urol 85(2):125\u2013138. https:\/\/doi.org\/10.1016\/j.eururo.2023.10.012","journal-title":"Eur Urol"},{"issue":"10288","key":"2107_CR31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","volume":"397","author":"AB Jani","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S et al (2021) 18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial. Lancet 397(10288):1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(21)00581-X","journal-title":"Lancet"},{"key":"2107_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1079808","volume":"13","author":"B Detti","year":"2023","unstructured":"Detti B, Carnevale MG et al (2023) Choline PET\/CT in recurrent prostate cancer. Front Oncol 13:1079808. https:\/\/doi.org\/10.3389\/fonc.2023.1079808","journal-title":"Front Oncol"},{"issue":"10338","key":"2107_CR33","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG et al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399(10338):1886\u20131901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6","journal-title":"Lancet"},{"issue":"16","key":"2107_CR34","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U et al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 389(16):1453\u20131465. https:\/\/doi.org\/10.1056\/NEJMoa2303974","journal-title":"N Engl J Med"},{"issue":"6","key":"2107_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","volume":"76","author":"E De Bleser","year":"2019","unstructured":"De Bleser E, Jereczek-Fossa BA et al (2019) Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol 76(6):732\u2013739. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.009","journal-title":"Eur Urol"},{"issue":"6","key":"2107_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S et al (2025) Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol 26(6):695\u2013706. https:\/\/doi.org\/10.1016\/S1470-2045(25)00197-4","journal-title":"Lancet Oncol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02107-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:29:41Z","timestamp":1770204581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02107-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02107-7","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. Prof. Lorenzo Livi and Prof. Isacco Desideri are editors in this Journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Comitato Etico Area Vasta Centro Prot.: 6787 del 19\/03\/2021.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}